Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 1/2012

01-07-2012 | Case Report

Elevation of pulmonary artery pressure as a complication of nilotinib therapy for chronic myeloid leukemia

Authors: Dariusz Zakrzewski, Ilona Seferynska, Krzysztof Warzocha, Tomasz Hryniewiecki

Published in: International Journal of Hematology | Issue 1/2012

Login to get access

Abstract

We present the case of a 72-year-old male with chronic phase myeloid leukemia. Elevation of the pulmonary artery pressure due to nilotinib therapy was noted. This effect on pulmonary artery pressure was nilotinib dose dependent.
Literature
1.
TASIGNA® (nilotinib) capsules prescribing information. Novartis Pharmaceuticals Corporation, East Hanover, NJ. 2010.
2.
Will Y, Dykens JA, Nadanaciva S, Hirakawa B, Jamieson J, Marroquin LD, et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007;110:1233–7.CrossRef
3.
Ribeiro AL, Marcolino MS, Bittencourt HN, Barbosa MM. An evaluation of the cardiotoxicity of imatinib mesylate. Leuk Res. 2008;32:1809–14.PubMedCrossRef
4.
Will Y, Dykens JA, Nadanaciva S, Hirakawa B, Jamieson J, Marroquin LD, et al. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib and sorafenib on mitochondria function in isolated rat heart mitochondria and H9c2 cells. Toxicol Sci. 2008;106:153–61.PubMedCrossRef
5.
Wolf A, Couttet P, Dong M, Grenet O, Heron M, Junker U, et al. Preclinical evaluation of potential nilotinib cardiotoxicity. Leuk Res. 2011;35:631–7.PubMedCrossRef
6.
Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res. 2009;33(6):861–4.PubMedCrossRef
7.
Orlandi EM, Rocca B, Pazzano AS, Ghio S. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res. 2012;36:e4–6.PubMedCrossRef
8.
Hennigs JK, Keller G, Baumann HJ, Honecker F, Kluge S, Bokemeyer C, et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med. 2011; 11:30.
9.
Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant. 2009;43:967–8.PubMedCrossRef
10.
Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med. 2010;182:1171–7.PubMedCrossRef
11.
Overbeek MJ, van Nieuw Amerongen GP, Boonstra A, Smit EF, Vonk-Noordegraaf A. Possible role of imatinib in clinical pulmonary veno-occlusive disease. Eur Respir J. 2008;32:232–5.PubMedCrossRef
12.
Williams MH, Handler CE, Akram R, Smith CJ, Das C, Smee J, Nair D, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J. 2006;27:1485–94.PubMedCrossRef
Metadata
Title
Elevation of pulmonary artery pressure as a complication of nilotinib therapy for chronic myeloid leukemia
Authors
Dariusz Zakrzewski
Ilona Seferynska
Krzysztof Warzocha
Tomasz Hryniewiecki
Publication date
01-07-2012
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 1/2012
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-012-1103-0

Other articles of this Issue 1/2012

International Journal of Hematology 1/2012 Go to the issue

Review Article

Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis

Review Article

Biological therapy and the immune system in patients with chronic myeloid leukemia

Original Article

Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation

Original Article

Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low- and low–intermediate risk, aggressive non-Hodgkin’s lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG9508

Case Report

Rituximab in a child with autoimmune thrombotic thrombocytopenic purpura refractory to plasma exchange

Letter to the Editor

On the prevalence and genetic predisposition of monoclonal gammopathy of undetermined significance (MGUS)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits